Intrust Bank NA Sells 83 Shares of argenex SE $ARGX

Intrust Bank NA cut its holdings in argenex SE (NASDAQ:ARGX) by 11.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 627 shares of the company’s stock after selling 83 shares during the period. Intrust Bank NA’s holdings in argenex were worth $346,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ARGX. WPG Advisers LLC purchased a new position in shares of argenex in the first quarter worth about $37,000. Brooklyn Investment Group grew its position in argenex by 102.7% during the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after acquiring an additional 38 shares during the last quarter. Banque Transatlantique SA bought a new position in argenex during the 1st quarter worth approximately $62,000. Geneos Wealth Management Inc. increased its stake in argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares during the period. Finally, Raiffeisen Bank International AG bought a new stake in argenex in the first quarter valued at approximately $76,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex Trading Down 1.2%

Shares of ARGX opened at $918.53 on Wednesday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.13. The firm’s 50-day moving average price is $805.61 and its 200-day moving average price is $676.75. The firm has a market capitalization of $56.55 billion, a price-to-earnings ratio of 39.44, a PEG ratio of 0.95 and a beta of 0.45.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. On average, research analysts forecast that argenex SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on ARGX shares. Citigroup raised their target price on shares of argenex from $1,041.00 to $1,124.00 and gave the stock a “buy” rating in a report on Monday. Morgan Stanley raised their price target on shares of argenex from $766.00 to $1,040.00 and gave the stock an “overweight” rating in a report on Wednesday, October 1st. Jefferies Financial Group set a $818.00 price objective on shares of argenex and gave the company a “buy” rating in a research note on Tuesday, August 26th. Wells Fargo & Company increased their target price on shares of argenex from $741.00 to $756.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. Finally, HC Wainwright boosted their price target on argenex from $774.00 to $915.00 and gave the company a “buy” rating in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $903.78.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.